Cleared Traditional

K112916 - TYSONBIO MD100 BLOOD GLUCSE MONITORING ,TYSONBIO MD100 PRO BLOOD GLUCISE MONITORING SYSTEM (FDA 510(k) Clearance)

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K112916 · Tyson Bioresearch, Inc. · Chemistry device
Aug 2012
Decision
323d
Days
Class 2
Risk

K112916 is an FDA 510(k) clearance for the TYSONBIO MD100 BLOOD GLUCSE MONITORING ,TYSONBIO MD100 PRO BLOOD GLUCISE MONI.... Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Tyson Bioresearch, Inc. (Chu-Nan, Miao-Li County, TW). The FDA issued a Cleared decision on August 21, 2012 after a review of 323 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

Submission Details

510(k) Number K112916 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 03, 2011
Decision Date August 21, 2012
Days to Decision 323 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Regulatory Context
Review time vs. panel average
89d slower than avg
Panel avg: 234d · This submission: 323d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 14
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K112916.
On Call® Sure GK Blood Glucose & Ketone Monitoring System
K250085 · ACON Laboratories, Inc. · Oct 2025
RIGHTEST Blood Glucose Monitoring System Max Tel
K240637 · Bionime Corporation · Nov 2024
RIGHTEST Blood Glucose Monitoring System Max Tel
K231192 · Bionime Corporation · Jan 2024
ReliOn Premier BLU Blood Glucose Monitoring System
K230625 · I-Sens, Inc. · Aug 2023
GlucoSure ADVANCE Link Blood Glucose Monitoring System
K222234 · Apex BioTechnology Corp. · Dec 2022
BGM039 Blood Glucose Monitoring System, BGM039 Link Blood Glucose Monitoring System
K220421 · Apex BioTechnology Corp. · Nov 2022